Fight against novel coronavirus: A perspective of medicinal chemists

The ongoing novel coronavirus disease (COVID-19) pandemic makes us painfully perceive that our bullet shells are blank so far for fighting against severe human coronavirus (HCoV). In spite of vast research work, it is crystal clear that the evident does not warrant the commercial blossoming of anti-HCoV drugs. In this circumstance, drug repurposing and/or screening of databases are the only fastest option. This study is an initiative to recapitulate the medicinal chemistry of severe acute respiratory syndrome (SARS)-CoV-2 (SARS-CoV-2). The aim is to present an exquisite delineation of the current research from the perspective of a medicinal chemist to allow the rapid development of anti-SARS-CoV-2 agents.

• Publication year

  2020

• Venue

  European journal of medicinal chemistry

• Publication date

  2020-06-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2020.112559PMID 32563814PMCID 7289749
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery

  2021cited by this paper
• The Novel Coronavirus: A Bird's Eye View

  2020cited by this paper
• Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.

  2020cited by this paper
• Structural basis of receptor recognition by SARS-CoV-2

  2020cited by this paper
• Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

  2020cited by this paper
• In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

  2020cited by this paper
• Fighting the Coronavirus Outbreak

  2020cited by this paper
• Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

  2020cited by this paper
• A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

  2020cited by this paper
• The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

  2020cited by this paper
• Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

  2020influential reference
• In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)

  2020cited by this paper
• In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

  2020cited by this paper
• Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

  2020cited by this paper
• Structure of the RNA-dependent RNA polymerase from COVID-19 virus

  2020influential reference
• In silico studies on therapeutic agents for COVID-19: Drug repurposing approach

  2020cited by this paper
• [Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP].

  2020cited by this paper
• A Review of SARS-CoV-2 and the Ongoing Clinical Trials

  2020cited by this paper
• Genomic characterization of a novel SARS-CoV-2

  2020cited by this paper
• Molecular Investigation of SARS–CoV-2 Proteins and Their Interactions with Antiviral Drugs

  2020influential reference
• Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus

  2020cited by this paper
• Déjà vu: Stimulating open drug discovery for SARS-CoV-2

  2020cited by this paper
• Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro

  2020influential reference
• Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study

  2020cited by this paper
• Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors

  2020cited by this paper
• Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo

  2020cited by this paper
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

  2020cited by this paper
• Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

  2020cited by this paper
• Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

  2020cited by this paper
• Recent discovery and development of inhibitors targeting coronaviruses

  2020cited by this paper
• Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

  2020influential reference
• A pneumonia outbreak associated with a new coronavirus of probable bat origin

  2020cited by this paper
• The global spread of 2019-nCoV: a molecular evolutionary analysis

  2020cited by this paper
• α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment

  2020cited by this paper
• Potential interventions for novel coronavirus in China: A systematic review

  2020cited by this paper
• 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies

  2020cited by this paper
• Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

  2020cited by this paper
• COVID‐2019: The role of the nsp2 and nsp3 in its pathogenesis

  2020cited by this paper
• Structure analysis of the receptor binding of 2019-nCoV

  2020cited by this paper
• Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

  2020influential reference
• Structure-Based Stabilization of Non-native Protein–Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design

  2020cited by this paper
• Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

  2020cited by this paper
• Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

  2020cited by this paper
• The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines

  2020cited by this paper
• Rapid Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease by Deep Docking of 1.3 Billion Compounds

  2020cited by this paper
• The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase

  2020cited by this paper
• Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.

  2020cited by this paper
• COVID-19 spike-host cell receptor GRP78 binding site prediction

  2020cited by this paper
• Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

  2020cited by this paper
• Exploring the structural aspects of ureido-amino acid-based APN inhibitors: a validated comparative multi-QSAR modelling study

  2020cited by this paper
• New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

  2020cited by this paper
• Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

  2020cited by this paper
• Teicoplanin potently blocks the cell entry of 2019-nCoV

  2020cited by this paper
• Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus

  2020cited by this paper
• Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

  2020cited by this paper
• Advance of promising targets and agents against COVID-19 in China

  2020cited by this paper
• An Imperative Need for Research on the Role of Environmental Factors in Transmission of Novel Coronavirus (COVID-19)

  2020cited by this paper
• Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

  2020cited by this paper
• Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

  2020cited by this paper
• FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro

  2020cited by this paper
• Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

  2020cited by this paper
• Coronavirus 2019-nCoV: A brief perspective from the front line

  2020cited by this paper
• Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

  2020cited by this paper
• Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery

  2019cited by this paper
• Synthesis, anticancer activity, structure-activity relationship and binding mode of interaction studies of substituted pentanoic acids.

  2019cited by this paper
• Anti-HCV

  2019cited by this paper
• Hydroxychloroquine

  2019cited by this paper
• SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

  2019cited by this paper
• Site-Directed Fragment-Based Screening for the Discovery of Protein-Protein Interaction Stabilizers.

  2019cited by this paper
• Design of Aminopeptidase N Inhibitors as Anti-cancer Agents.

  2018cited by this paper
• Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review

  2018cited by this paper
• PPI inhibitor and stabilizer development in human diseases.

  2017cited by this paper
• Structural Insight Into the Viral 3C-Like Protease Inhibitors: Comparative SAR/QSAR Approaches

  2017cited by this paper
• Structure, Function, and Evolution of Coronavirus Spike Proteins.

  2016cited by this paper
• Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

  2016influential reference
• Coronaviruses — drug discovery and therapeutic options

  2016cited by this paper
• Nitazoxanide: A first-in-class broad-spectrum antiviral agent

  2014cited by this paper
• Exploration of structural and physicochemical requirements and search of virtual hits for aminopeptidase N inhibitors

  2013cited by this paper
• SARS-CoV ORF1b-encoded nonstructural proteins 12–16: Replicative enzymes as antiviral targets

  2013cited by this paper
• Ribavirin

  2011cited by this paper
• Coronaviruses post-SARS: update on replication and pathogenesis

  2009cited by this paper
• Nitazoxanide: a new thiazolide antiparasitic agent.

  2005cited by this paper
• Structural Basis of Severe Acute Respiratory Syndrome Coronavirus ADP-Ribose-1″-Phosphate Dephosphorylation by a Conserved Domain of nsP3

  2005cited by this paper
• Structure

  2004cited by this paper
• Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

  2003cited by this paper
• Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum.

  1993cited by this paper
• Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease.

  1967cited by this paper
• A New Virus Isolated from the Human Respiratory Tract.∗

  1966cited by this paper

• Designing Chalcone-Amide Derivatives as Novel Inhibitors of SARS-CoV-2 Papain-like Protease using 3D-QSAR Modeling, Molecular Docking, Quantum Mechanical Calculations, and Molecular Dynamics Simulations

  2026cites this paper
• Structural-based virtual screening of Ebselen derivatives to identify potential SARS-CoV-2 main protease inhibitors, utilizing 3D-QSAR models, molecular docking, MD simulation, and quantum mechanical calculations

  2025cites this paper
• Decoding SARS‐CoV‐2 Inhibition: Insights From Molecular Dynamics Simulation of Condensed Amino Thiourea Scaffold Small Molecules

  2025cites this paper
• Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme

  2025cites this paper
• Discovery of Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors through Rational Design of Novel Fluorinated 1,3,4‐oxadiazole Amide Derivatives: An In‐Silico Study

  2025cites this paper
• Accurate prediction of dynamic protein–ligand binding using P‐score ranking

  2024cites this paper
• Small molecules in the race of COVID-19 drug development

  2023cites this paper
• A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design

  2023cites this paper
• Synthesis of Functionalized 2′,5‐Oxo‐spiro[furan‐2,3′‐indoline]‐3‐carboxylate Derivatives as Antiproliferative Agents: ADMET Studies, and Molecular Docking against P2Y12 Inhibitors

  2023cites this paper
• The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

  2023cites this paper
• A quinoline-benzotriazole derivative: Synthesis, crystal structure and characterization by using spectroscopic, DFT and molecular docking methods

  2023cites this paper
• Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors

  2022cites this paper
• Acriflavine and proflavine hemisulfate as potential antivirals by targeting Mpro

  2022cites this paper
• Development of a deep learning-based quantitative structure-activity relationship model to identify potential inhibitors against the 3C-like protease of SARS-CoV-2.

  2022cites this paper
• Molecular Docking: Principles, Advances, and its Applications in Drug Discovery

  2022cites this paper
• Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2

  2022cites this paper
• Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies

  2022cites this paper
• Molnupiravir: First Approval

  2022cites this paper
• In silico approach for the development of novel antiviral compounds based on SARS-COV-2 protease inhibition

  2022influential citation
• Repositioning anticancer drugs as novel COVID-19 antivirals: targeting structural and functional similarities between viral proteins and cancer

  2022cites this paper
• Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

  2022cites this paper
• Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

  2022cites this paper
• Applicability of vitamins in the management of COVID-19: An overview

  2021cites this paper
• In silico analysis of Phyllanthus amarus phytochemicals as potent drugs against SARS-CoV-2 main protease

  2021cites this paper
• Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease

  2021cites this paper
• Computational screening of natural compounds from Salvia plebeia R. Br. for inhibition of SARS-CoV-2 main protease

  2021cites this paper
• In silico screening of antiviral compounds from Moringa oleifera for inhibition of SARS-CoV-2 main protease

  2021cites this paper
• Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

  2021cites this paper
• Synthesis of Isatin Derivatives Using Silver Nanoparticles as Green Catalyst: Study of Molecular Docking Interactions in SARS-CoV-2 3c-Like Protease and Determination of Cytotoxic Activities of the Compounds

  2021cites this paper
• Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences

  2021cites this paper
• An Overview of the Curcumin-Based and Allicin Bioactive Compounds as potential treatment to SARS-CoV-2 with structural bioinformatics tools

  2021cites this paper
• DEVELOPMENT OF EFFERVESCENT TABLETS BASED ON RED GINGER (ZINGIBER OFFICINALE ROSC. VAR. RUBRUM) AND ROSELLA FLOWER (HIBISCUS SABDARIFFA L.)

  2021influential citation
• CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy

  2021cites this paper
• First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery

  2021cites this paper
• Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19

  2021cites this paper
• The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2

  2021cites this paper
• SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

  2021cites this paper
• Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic

  2021cites this paper
• Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein

  2021cites this paper
• An update review of emerging small-molecule therapeutic options for COVID-19

  2021influential citation
• Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?

  2021cites this paper
• Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery

  2021cites this paper
• Unmasking of crucial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery

  2021cites this paper
• In-Silico Structure-Based Drug Discovery of Candidate Drugs against Novel Protein Receptor Complex Nsp10-Nsp16 of SARS-CoV-2 using Drug Repurposing Approach

  2021cites this paper
• Resources for Docking-Based Virtual Screening

  2021cites this paper
• Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CLpro inhibitors: theoretical justification in light of experimental evidences

  2021cites this paper
• Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options

  2021influential citation
• Main Chemotypes of SARS-CoV-2 Reproduction Inhibitors

  2021cites this paper
• SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?

  2021cites this paper
• Investigation of Cepharanthine Binding with Viral Proteins Reveal its Potential Targets against Coronavirus

  2021cites this paper
• Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors

  2021cites this paper
• Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study

  2021cites this paper
• An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19

  2021cites this paper
• Coronavirus 2019-nCoV: A brief perspective from the front line

  2020cites this paper
• Molecular Docking Studies on Synthetic Therapeutic Agents for COVID-19

  2020cites this paper
• The Pharmaceuticals Using for COVID-19 Patients and in Silico Natural Product Studies about COVID-19

  2020cites this paper
• Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques

  2020cites this paper
• Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (MPRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model.

  2020cites this paper
• Biflavonoids from Rhus succedanea as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach

  2020influential citation
• Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors

  2020cites this paper
• An in silico perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of COVID-19

  2020cites this paper
• Small molecule stabilization of non-native protein-protein interactions of SARS-CoV-2 N protein as a mechanism of action against COVID-19

  2020cites this paper
• Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs

  2020cites this paper
• Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19

  2020cites this paper
• Are open-source approaches the most efficient way forward for COVID-19 drug discovery?

  2020cites this paper
• Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) inhibitors

  2020cites this paper
• Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives

  2020cites this paper
• Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus

  2020cites this paper
• In silico screening of antiviral compounds from Moringa oleifera for inhibition of SARS-CoV-2 main protease

  year unknowncites this paper